Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
A growing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of…
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one…
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer-…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
DRG Epidemiology’s coverage of human papilloma virus comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…
DRG Epidemiology's coverage of RSV comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain,…
DRG Epidemiology's coverage of the RSV vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany…
Myasthenia gravis (MG) is an acquired disorder of neuromuscular transmission, which occurs due to the production of pathogenic autoantibodies that bind to components of the neuromuscular junction,…
The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of Roche / Genentech…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…